Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results
Ultragenyx reports Phase 3 Aspire study of apazunersen failed to meet primary endpoints, prompting plans for expense cuts.
Ultragenyx's medicine didn't work as well as hoped in testing, so the company is spending less money to save cash. When a drug company has bad test results, watch whether they can still make money with their other products.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.